Influence of intravesical administration of tumor necrosis factor ? and systemic ?-interferon on murine bladder cancer: Lack of dose response
✍ Scribed by Lee, K. ;O'Donnell, R. W. ;Cockett, A. T. K.
- Publisher
- Springer
- Year
- 1990
- Tongue
- English
- Weight
- 215 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0300-5623
No coin nor oath required. For personal study only.
✦ Synopsis
The effect of intravesical administration of high dose recombinant tumor necrosis factor-alpha (rTNF) and in combination with systemic recombinant gamma-interferon (rIFN) on murine bladder cancer was studied. RTNF was given at 12.5 micrograms/mouse on days 7, 11 and 15 after tumor instillation or at 2.5 micrograms/mouse on days 7, 9, 11, 13 and 15. Some groups were also injected i.v., 24-h prior to each rTNF treatment with rIFN at a dose of 1.3 micrograms/mouse. RTNF treatment suppressed tumor growth up to 48% of control, although the difference was not statistically significant. Combined administration of rIFN did not provide additional benefit.